CoChat

Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma

Hirata, Hidenari, Sugimachi, Keishi, Komatsu, Hisateru, Ueda, Masami, Masuda, Takaaki, Uchi, Ryutaro, Sakimura, Shotaro, Nambara, Sho, Saito, Tomoko, Shinden, Yoshiaki, Iguchi, Tomohiro, Eguchi, Hidetoshi, Ito, Shuhei, Terashima, Kotaro, Sakamoto, Katsumi, Hirakawa, Masakazu, Honda, Hiroshi, Mimori, Koshi · 2016 · Cancer Research
Cited by 150

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Fructose-1,6-bisphosphatase (FBP1), the rate-limiting enzyme in gluconeogenesis, is reduced in expression in certain cancers where it has been hypothesized to act as a tumor suppressor, including in hepatocellular carcinoma (HCC). Here, we report functional evidence supporting this hypothesis, providing a preclinical rationale to develop FBP1 as a therapeutic target for HCC treatment. Three independent cohorts totaling 594 cases of HCC were analyzed to address clinical significance. Lower FBP1 expression associated with advanced tumor stage, poor overall survival, and higher tumor recurrence rates. In HCC cell lines, where endogenous FBP1 expression is low, engineering its ectopic overexpression inhibited tumor growth and intracellular glucose uptake by reducing aerobic glycolysis. In patient specimens, promoter methylation and copy-number loss of FBP1 were independently associated with decreased FBP1 expression. Similarly, FBP1 downregulation in HCC cell lines was also associated with copy-number loss. HCC specimens exhibiting low expression of FBP1 had a highly malignant phenotype, including large tumor size, poor differentiation, impaired gluconeogenesis, and enhanced aerobic glycolysis. The effects of FBP1 expression on prognosis and glucose metabolism were confirmed by gene set enrichment analysis. Overall, our findings established that FBP1 downregulation in HCC contributed to tumor progression and poor prognosis by altering glucose metabolism, and they rationalize further study of FBP1 as a prognostic biomarker and therapeutic target in HCC patients. Cancer Res; 76(11); 3265–76. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-15-2601

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 150

Metadata

Authors
Hirata, H., Sugimachi, K., Komatsu, H., Ueda, M., Masuda, T., Uchi, R., Sakimura, S., Nambara, S., Saito, T., Shinden, Y., Iguchi, T., Eguchi, H., Ito, S., Terashima, K., Sakamoto, K., Hirakawa, M., Honda, H., & Mimori, K.
Venue
Cancer Research
Published
2016-05-31
Volume
76
Issue
11
Pages
3265-3276
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2322763157
Cited by
150
References
8
FWCI
4.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-15-2601
The paper
Hirata, H., Sugimachi, K., Komatsu, H., Ueda, M., Masuda, T., Uchi, R., Sakimura, S., Nambara, S., Saito, T., Shinden, Y., Iguchi, T., Eguchi, H., Ito, S., Terashima, K., Sakamoto, K., Hirakawa, M., Honda, H., & Mimori, K. (2016). Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-15-2601

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.